GLP-1 receptor agonists may offer cardiovascular benefits in women with type 2 diabetes and breast cancer, although randomized trial data are necessary for confirmation.
Do GLP-1 receptor agonists improve cardiovascular outcomes in female breast cancer survivors with type 2 diabetes?
GLP-1 receptor agonists may provide cardiovascular benefits for female breast cancer survivors with type 2 diabetes in real-world clinical practice.
This study demonstrated the potential CV benefit of GLP-1 RA therapies among a population of female breast cancer survivors with T2D. Randomized trial data are needed to confirm these findings.
Cornelio et al. (2026) studied this question. GLP-1 receptor agonists may offer cardiovascular benefits in women with type 2 diabetes and breast cancer, although randomized trial data are necessary for confirmation.